NMOSD News Briefs

medical vials

New Trial Sets Out to Evaluate Mitoxantrone Hydrochloride in NMOSD

A new multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial aims to assess the safety and effectiveness of mitoxantrone hydrochloride liposome injection in patients with neuromyelitis optica spectrum disorder (NMOSD). The study will include 45 patients aged between 18 and 60 years with an NMOSD diagnosis made as determined by the 2015 International Consensus Diagnostic…

Headache

High Pain Incidence Identified Among Patients With NMOSD

There is a high prevalence of pain among patients with neuromyelitis optica spectrum disorder (NMOSD), and identifying this pain may be useful in localizing the disease, says a new retrospective study published in the journal Multiple Sclerosis and Related Disorders. The presence of aquaporin-4 antibody (AQP4-ab) in serum is an independent risk factor for NMOSD pain.…

CSF

Factors Found in CSF Predict Progression and Disease Severity of NMOSD

B cell-activating factor (BAFF) and aquaporin-4 antibody (AQP4-Ab) concentrations in the cerebrospinal fluid (CSF) are correlated with the severity of neuromyelitis optica spectrum disorder (NMOSD), according to a new study published in the Turkish Journal of Biochemistry. These concentrations can also predict the progression of the disease. To evaluate the correlation between the severity of…

NMOSD Prognosis

Severe Axonal Damage Found in Patients With Optic Neuritis Due to NMOSD

Patients with optic neuritis related to neuromyelitis optica spectrum disorder (NMOSD) have more severe axonal damage and worse axonal recovery compared to those with idiopathic demyelinating optic neuritis, found a new study published in BMC Ophthalmology.   The researchers also reported that visual evoked potential elicited by smaller check size is more sensitive to visual…

cognitive decline brain

Novel Tool Used to Assess Cognitive Impairment Risk in Patients With NMOSD

Researchers from China developed a new classification scheme for cognitive impairments in patients with neuromyelitis optica spectrum disorder (NMOSD), a recent study suggests. Based on the scheme, the deterioration of motor ability in the arms and legs of the patients can potentially predict cognitive phenotypes in NMOSD. The findings were recently published in the journal…

brain illustration

Functional Connectivity Alterations in NMOSD May Improve Clinical Outcomes

Patients with myelitis due to neuromyelitis optica spectrum disorder (NMOSD) may experience functional alternations in several brain regions. Some of these changes may be associated with better clinical performance and could play a role in NMOSD rehabilitation, according to a recently published study in Multiple Sclerosis and Related Disorders. Several studies have shown a correlation between…

3d illustration of human body eye anatomy

Retinal Optical Coherence Tomography May Help Diagnose Probable NMOSD

Retinal optical coherence tomography measurements in patients with potential and definite neuromyelitis optica spectrum disorder (NMOSD) are significantly lower than in patients with multiple sclerosis (MS) and healthy people, according to the results of a new study that appeared in the journal Multiple Sclerosis and Related Disorders.  The measurements could therefore be helpful in supporting…

NMOSD treatment

ALS Drug Could Lead to Lesion Repair in Patients With NMOSD

Edaravone (Radicava®) could promote lesion repair in patients with neuromyelitis optica spectrum disorder (NMOSD) by improving the maturation of oligodendrocyte progenitor cells, according to a new study. These data showed that edaravone improved motor function in a systemic mouse model of NMOSD. It also increased remyelination in organotypic slice cultures as well as the mice,…

NMOSD Prognosis

Autologous Hematopoietic Stem Cell Transplantation Shows Promise for Severe NMOSD

For patients with severe neuromyelitis optica spectrum disorder (NMOSD), autologous hematopoietic stem cell transplantation (AHSCT) may be used as an alternative to traditional immunotherapies, according to a systematic review and meta-analysis. These data indicated that the Extended Disability Status Scale score prior to and following AHSCT had a pooled standardized mean difference of -0.81 (95%…

NMOSD treatment

Batoclimab Appears Safe and Effective in NMOSD

Batoclimab, a neonatal Fc receptor (FcRn) antagonist, has shown neurological benefits in neuromyelitis optica spectrum disorder (NMOSD) when combined with intravenous methylprednisolone pulse (IVMP), according to a recently published study. Although IVMP remains the most commonly used therapy for acute NMOSD attacks, only a minority of patients that receive it experience complete remission. Over 15%…

Next post in NMOSD News Briefs